SCHEMBL2276918

SCHEMBL2276918

O=C(Nc1cc(/C=C/c2ccc(F)cc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 4/20 0.66
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
PKM P14618 2/20 0.56
MAPT P10636 1/20 0.56
GRIK1 P39086 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
TRPA1 O75762 1/20 0.55
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.49
KCNK3 O14649 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
KCNK2 O95069 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
BCL2L1 Q07817 1/20 0.47
BAD Q92934 1/20 0.47
PTPN1 P18031 1/20 0.47
KDM4D Q6B0I6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276923 1.00 SNCA (0.66) SNCAMEN1KMT2APKMMAPT
SCHEMBL27716652 0.96 SNCA (0.63) SNCAMEN1KMT2APKMMAPT
SCHEMBL2276655 0.92 PKM (0.62) SNCAMEN1KMT2APKMMAPT
SCHEMBL2276651 0.92 PKM (0.62) SNCAMEN1KMT2APKMMAPT
SCHEMBL2272560 0.91 KMT2A (0.55) SNCAMEN1KMT2APKMMAPT
SCHEMBL2272567 0.91 KMT2A (0.55) SNCAMEN1KMT2APKMMAPT
SCHEMBL2269167 0.89 SNCA (0.59) SNCAMEN1KMT2APKMMAPT
SCHEMBL2269158 0.89 SNCA (0.59) SNCAMEN1KMT2APKMMAPT
SCHEMBL27696878 0.89 SNCA (0.57) SNCAMEN1KMT2APKMMAPT
SCHEMBL27716729 0.88 SNCA (0.53) SNCAMEN1KMT2APKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SNCA 4741/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.